Caplin Point Laboratories (BOM:524742) Change In Working Capital : ₹0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Caplin Point Laboratories Change In Working Capital?

Caplin Point Laboratories's change in working capital for the quarter that ended in Mar. 2024 was ₹0 Mil.

Caplin Point Laboratories's change in working capital for the fiscal year that ended in Mar. 2024 was ₹-1,393 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Caplin Point Laboratories Change In Working Capital Historical Data

The historical data trend for Caplin Point Laboratories's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caplin Point Laboratories Change In Working Capital Chart

Caplin Point Laboratories Annual Data

Trend

Jun15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Working Capital

Get a 7-Day Free Trial

-1,925.00

55.20

19.60

-1,037.50

-1,392.60

Caplin Point Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															-	-	-	-	-

Caplin Point Laboratories Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Caplin Point Laboratories Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Caplin Point Laboratories's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Caplin Point Laboratories (BOM:524742) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Caplin Point Laboratories Ltd (BOM:524742) » Definitions » Change In Working Capital

Traded in Other Exchanges

CAPLIPOINT:India

Address

Ashvich Tower, Developed Plots Industrial Estate, No. 3, 3rd Floor, Perungudi, Chennai, TN, IND, 600 096

Website

https://www.caplinpoint.net

Caplin Point Laboratories Ltd is the India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, liquid orals, dry powder, soft gels, penems injections, suppositories. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops. The business of the company is organized into the following product segments, Antibiotics, Nsaids, Ophthalmics, Pain Management, and Antiulcers. Its products have a presence in the Latin American and African markets.

Caplin Point Laboratories (BOM:524742) Headlines

No Headlines